Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 5 of 12, showing 5 Applications out of 59 total, starting on record 21, ending on 25

# Protocol No Study Title Investigator(s) & Site(s)

21.

ECCT/23/11/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. In this submission: International Cancer Institute (Uasin Gishu county)
 
View

22.

ECCT/14/11/02   A5297
    An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3   
Principal Investigator(s)
1. VICTOR AKELO
Site(s) in Kenya
KEMRI/CDC CLINICAL RESEARCH CENTRE
 
View

23.

ECCT/19/03/01   Validation of syringe extension device
    Validation of re-usable, low cost syringe extension device for the provision of paracervical analgesia during gynecological procedures   
Principal Investigator(s)
1. Stephen Gwer
2. Aparna Ramanathan
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Kisumu County Hospital (Kisumu county)
3. God\'s Will Clinic (Kisumu county)
4. Marie Stopes Kenya-Kisumu Clinic (Kisumu county)
 
View

24.

ECCT/19/11/03   A Pilot BE study for Enalpril 5mg
    A bioequivalent pilot study of a locally-produced brand of enalapril tablets:  a key step towards implementation of bioequivalent study regulatory requirements in East Africa   
Principal Investigator(s)
1. Simon Njoroge Njenga
Site(s) in Kenya
Kenya Medical Research Institute
 
View

25.

ECCT/22/04/02   GO42144
    A PHASE Ia/Ib DOSE-ESCALATION AND DOSE- EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITYOF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS        
Principal Investigator(s)
1. Mansoor Noorali Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View